Screener
Avalo Therapeutics AVTX Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 7,607 | 6,913 |
| Restricted cash, current portion | 49 | 37 |
| Total current assets | 407,932 | 105,286 |
| Long-term investments | 71,878 | — |
| Property and equipment, net | 288 | 460 |
| Goodwill | 10,502 | 10,502 |
| Restricted cash, net of current portion | 183 | 210 |
| Total assets | $490,783 | $116,458 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's equity method investments?
- Avalo Therapeutics (AVTX) reported equity method investments of $71.88M in Q2 2026.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Avalo Therapeutics's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude